p53 and mdm2 as prognostic indicators in patients with epithelial ovarian cancer: A multivariate analysis

Gynecologic Oncology

Volumn 97, Issue 1, 2005, Pages 46-52

  Dogan, Erbil ^a   Saygili, Ugur ^a   Tuna, Burçin ^a   Gol, Mert ^a   Gürel, Duygu ^a   Acar, Berrin ^a   Koyuncuoǧlu, Meral ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Epithelial ovarian cancer; mdm2; p53; Prognosis

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PROTEIN MDM2; PROTEIN P53; TUMOR MARKER;

ARTICLE; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CHEMOSENSITIVITY; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOREDUCTIVE SURGERY; DISEASE MARKER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; SURVIVAL RATE; TUMOR BIOPSY;

EID: 15544371613     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ygyno.2004.12.053     Document Type: Article

References (36)

1. I.B. Runnebaum, and E. Stickeler Epidemiological and molecular aspects of ovarian cancer risk J. Cancer Res. Clin. Oncol. 127 2001 73 79
2. M.L. Friedlander Prognostic factors in ovarian cancer Semin. Oncol. 25 3 1998 305 314
3. F. Chang, S. Syrjanen, and K. Syrjanen Implications of the p53 tumor-suppressor gene in clinical oncology J. Clin. Oncol. 13 1995 1009 1022
4. R. Iggo, K. Gatter, J. Bartek, D. Lane, and A.L. Harris Increased expression of mutant forms of p53 oncogene in primary lung cancer Lancet 335 1990 675 679
5. W.H. Wen, A. Reles, I.B. Runnebaum, J. Sullivan-Halley, L. Bernstein, and L.A. Jones p53 mutations and expression in ovarian cancers: correlation with overall survival Int. J. Gynecol. Pathol. 18 1999 29 41
6. D. Marx, H. Meden, T. Ziemek, T. Lenthe, W. Kuhn, and A. Schauer Expression of the p53 tumor suppressor gene as a prognostic marker in platinum-treated patients with ovarian cancer Eur. J. Cancer 34 1998 845 850
7. M.S. Greenblatt, W.P. Bennett, M. Hollstein, and C.C. Harris Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis Cancer Res. 54 1994 4855 4878
8. S. Kondo, G.H. Barnett, H. Hara, T. Morimura, and J. Takeuchi MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis Oncogene 10 1995 2001 2006
9. B. Tuna, K. Yorukoglu, E. Tuzel, M. Guray, U. Mungan, and Z. Kirkali Expression of p53 and mdm2 and their significance in recurrence of superficial bladder cancer Pathol. Res. Pract. 199 2003 323 328
10. R. Henriksen, P. Strang, E. Wilnder, T. Backstrom, B. Tribukait, and K. Oberg p53 Expression in epithelial ovarian neoplasms: relationship to clinical and pathological parameters, Ki-67 expression and flow cytometry Gynecol. Oncol. 53 1994 301 306
11. P.J. Klemi, L. Pylkkanen, P. Kiilholma, K. Kurvinen, and H. Joensuu p53 protein detected by immunohistochemistry as a prognostic factor in patients with epithelial ovarian carcinoma Cancer 76 1995 1201 1208
12. M.A. Levesque, D. Katsaros, H. Yu, P. Zola, P. Sismondi, and G. Giardina Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma Cancer 75 1995 1327 1338
13. J.P. Geisler, H.E. Geisler, M.C. Wiemann, S.S. Givens, Z. Zhou, and G.A. Miller Quantification of p53 in epithelial ovarian cancer Gynecol. Oncol. 66 1997 435 438
14. P. Rohlke, K. Milde-Langosch, C. Weyland, U. Pichlmeier, W. Jonat, and T. Loning p53 is a persistant and predictive marker in advanced ovarian carcinomas: multivariate analysis including comparison with Ki-67 immunoreactivity J. Cancer Res. Clin. Oncol. 123 1997 496 501
15. G. Viale, P. Maisonnneuve, E. Bonoldi, A. Di Bacco, P. Bevilacqua, and G.A. Panizzoni The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labeling index provided independent information on overall survival of ovarian carcinoma patients Ann. Oncol. 8 1997 469 476
16. L.C. Hartmann, K.C. Podratz, G.L. Keeney, N.A. Kamel, J.H. Edmonson, and J.P. Grill Prognostic significance of p53 immunostaining in epithelial ovarian cancer J. Clin. Oncol. 12 1994 64 69
17. G.H. Eltabbakh, J.L. Belinson, A.W. Kennedy, C.V. Biscotti, G. Casey, and R.R. Tubbs p53 overexpression is not an independent prognostic factor for patients with primary ovarian epithelial cancer Cancer 80 1997 892 898
18. R. Silvestrini, M.G. Daidone, and S. Veneroni The clinical predictivity of biomarkers of stage III-IV epithelial ovarian cancer in a prospective randomized treatment protocol Cancer 82 1998 159 167
19. Y. Hashiguchi, H. Tsuda, T. Inoue, S. Nishimura, T. Suzuki, and N. Kawamura Alteration of cell cycle regulators correlates with survival in epithelial ovarian cancer patients Hum. Pathol. 35 2004 165 175
20. J. Hall, J. Paul, and R. Brown Critical evaluation of p53 as a prognostic marker in ovarian cancer Expert Rev. Mol. Med. 6 2004 1 20
21. M. Tachibana, J. Watanabe, Y. Matsushima, K. Nishida, Y. Kobayashi, and M. Fujimura Independence of the prognostic value of tumor suppressor protein expression in ovarian adenocarcinomas: a multivariate analysis of expression of p53, retinoblastoma, and related proteins Int. J. Gynecol. Cancer 13 2003 598 606
22. M.A. Anttila, H. Ji, M.T. Juhola, S.V. Saarikoski, and K.J. Syrjanen The prognostic significance of p53 expression quantitated by computerized image analysis in epithelial ovarian cancer Int. J. Gynecol. Pathol. 18 1999 42 51
23. L. Havrilesky, M. Darcy, H. Hamdan, R.L. Priore, J. Leon, and J. Bell Prognostic significance of p53 mutation and p53 overexpression in advanced epithelial ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 21 2003 3814 3825
24. U. Saygili, S. Guclu, T. Uslu, O. Erten, and E. Dogan The effect of ascites, mass volume, and peritoneal carcinomatosis on serum CA125 levels in patients with ovarian carcinoma Int. J. Gynecol. Cancer 12 2002 438 442
25. P. Chene Inhibition of the p53-mdm2 interaction: targeting a protein-protein interface Mol. Cancer Res. 2 2004 20 28
26. L.T. Vassilev, B.T. Vu, B. Graves, D. Carvajal, F. Podlaski, and Z. Filipovic In vivo activation of the p53 pathway by small-molecule antagonists of mdm2 Science 303 2004 844 848
27. W.D. Foulkes, G.W. Stamp, S. Afzal, N. Lalani, C.P. McFarlane, and J. Trowsdale MDM2 overexpression is rare in ovarian carcinoma irrespective of TP53 mutation status Br. J. Cancer 72 1995 883 888
28. B. Tanner, J.G. Hengstler, S. Laubscher, R. Meinert, F. Oesch, and W. Weikel mdm 2 mRNA expression is associated with survival in ovarian cancer Int. J. Cancer 74 1997 438 442
29. S. Ginath, J. Menczer, Y. Friedmann, H. Aingorn, A. Aviv, and K. Tajima Expression of heparanase, Mdm2, and erbB2 in ovarian cancer Int. J. Oncol. 18 2001 1133 1144
30. A. Harlozinska, J. Bar, and M. Montenarh Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas Anticancer Res. 20 2000 1049 1056
31. F. Courjal, M. Cuny, C. Rodriguez, G. Louason, P. Speiser, and D. Katsaros DNA amplifications at 20q13 and MDM2 define distinct subsets of evolved breast and ovarian tumors Br. J. Cancer 74 1996 1984 1989
32. H. Skomedal, G.B. Kristensen, V.M. Abeler, A.L. Borresen-Dale, C. Trope, and R. Holm TP53 protein accumulation and gene mutation in relation to overexpression of MDM2 protein in ovarian borderline tumors and stage I carcinomas J. Pathol. 181 1997 158 165
33. Y. Mano, Y. Kikuchi, K. Yamamoto, T. Kita, J. Hirata, and T. Tode Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer Eur. J. Cancer 35 1999 1214 1219
34. R. Agarwal, and S.B. Kaye Ovarian cancer: strategies for overcoming resistance to chemotherapy Nat. Rev., Cancer 3 2003 502 516
35. P. Perego, M. Giarola, S.C. Righetti, R. Supino, C. Caserini, and D. Delia Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems Cancer Res. 56 1996 556 562
36. U. Saygili, S. Guclu, T. Uslu, O. Erten, N. Demir, and A. Onvural Can serum CA-125 levels predict the optimal primary cytoreduction in patients with advanced ovarian carcinoma? Gynecol. Oncol. 86 2002 57 61